天臣医疗(688013) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 60,219,598.04, representing a year-on-year increase of 1.26%[6] - The net profit attributable to shareholders was CNY 11,352,005.37, showing a decrease of 2.97% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was CNY 11,011,201.10, which increased by 22.24% year-on-year[6] - The company's net profit for Q1 2024 is not explicitly stated but can be inferred from the operating revenue and costs, indicating a potential increase in profitability[21] - The company reported a total comprehensive income of CNY 11,402,462.19 for Q1 2024, compared to CNY 11,669,542.14 in Q1 2023, reflecting a decline of about 2.29%[23] - The net profit for Q1 2024 was CNY 11,352,005.37, a decrease from CNY 11,699,630.75 in Q1 2023, representing a decline of approximately 2.96%[22] - The company's operating profit for Q1 2024 was CNY 12,496,219.62, slightly up from CNY 12,462,951.36 in Q1 2023, marking an increase of about 0.27%[22] Cash Flow - The net cash flow from operating activities was CNY 8,792,670.81, reflecting a significant decrease of 51.96% compared to the previous year[6][10] - The cash flow from operating activities netted CNY 8,792,670.81, down from CNY 18,303,016.75 in Q1 2023, indicating a decrease of approximately 52.0%[27] - The company's cash flow from operating activities showed a significant improvement, with a net cash inflow of CNY 10,255,954.38 in Q1 2024 compared to CNY 8,263,180.53 in Q1 2023[37] - The company incurred a net cash outflow from financing activities of CNY -35,892,650.30 in Q1 2024, compared to CNY -184,350.79 in Q1 2023[28] - The cash inflow from investment activities was CNY 173,599,630.17, down from CNY 229,247,703.83 in the previous year, indicating a decrease of approximately 24.4%[28] - The net cash flow from investment activities improved to $12,987,936.31 in Q1 2024, compared to a negative $18,939,776.42 in Q1 2023[39] - The net cash flow from financing activities was negative at -$35,739,128.00, compared to -$124,800.00 in Q1 2023[39] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 600,009,557.85, down 4.24% from the end of the previous year[7] - The company's cash and cash equivalents as of March 31, 2024, were RMB 198,129,775.32, down from RMB 211,533,558.01 at the end of 2023, a decline of approximately 6.32%[16] - Total liabilities decreased to RMB 47,318,440.64 in Q1 2024 from RMB 55,084,046.36 in Q1 2023, a decline of approximately 14.09%[18] - The company's equity attributable to shareholders decreased to RMB 552,691,117.21 as of March 31, 2024, from RMB 571,524,539.79 at the end of 2023, a decline of about 3.29%[18] - The total assets decreased to CNY 612,848,822.67 in Q1 2024 from CNY 640,931,269.07 in Q1 2023, a decline of 4.4%[32] - The total liabilities decreased to CNY 44,099,842.11 in Q1 2024 from CNY 52,202,358.12 in Q1 2023, a reduction of 15.5%[32] Research and Development - Research and development expenses totaled CNY 7,098,705.62, which is a decrease of 10.76% year-on-year[6] - The proportion of R&D expenses to operating revenue was 11.79%, down 1.58 percentage points from the previous year[6] - Research and development expenses for Q1 2024 were RMB 7,098,705.62, compared to RMB 7,954,185.12 in Q1 2023, reflecting a decrease of about 10.77%[21] - Research and development expenses for Q1 2024 were CNY 7,098,705.62, down from CNY 7,954,185.12 in Q1 2023, indicating a decrease of 10.8%[35] Other Income and Expenses - The company reported a significant increase in other income to RMB 351,419.37 in Q1 2024 from RMB 158,305.49 in Q1 2023, representing a growth of approximately 121.54%[21] - The company reported a tax expense of CNY 1,009,214.25 for Q1 2024, which is an increase from CNY 722,657.67 in Q1 2023, representing a rise of approximately 39.8%[22] - The basic and diluted earnings per share remained stable at CNY 0.14 for both Q1 2024 and Q1 2023[23] Inventory and Contract Liabilities - The company's inventory increased to CNY 29,165,472.92 in Q1 2024 from CNY 23,952,975.39 in Q1 2023, reflecting a rise of 21.5%[35] - The company's contract liabilities decreased to CNY 6,084,721.08 in Q1 2024 from CNY 16,615,406.78 in Q1 2023, a decrease of 63.4%[32]